4/A: Protara Therapeutics CFO Corrects Beneficial Ownership Report
SEC Filing (Form 4 Amendment)
Patrick Fabbio, CFO of Protara Therapeutics, files an amended Form 4 to correct a previously misreported amount of securities beneficially owned.
Summary
- Patrick Fabbio, the Chief Financial Officer of Protara Therapeutics, filed an amended Form 4 on March 28, 2025.
- This amendment corrects a previous filing from January 28, 2025, which inadvertently misreported the amount of securities beneficially owned by Fabbio following a reported transaction.
- The corrected filing indicates that Fabbio directly owns 42,439 shares of Protara Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing amendment, indicating a neutral event. The correction of an error is a positive sign of transparency.
Industry Context
Form 4 filings are a routine part of compliance for company insiders and large shareholders, providing transparency into their transactions in the company's stock. Amendments are also common and can be due to administrative errors.
Stakeholder Impact
- The correction of the filing ensures accurate information for shareholders and potential investors.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of earliest transaction |
| 01/28/2025 | Date of original Form 4 filed which contained an error |
| 03/28/2025 | Date of amended Form 4 filing |
Keywords
Form 4, Beneficial Ownership, Amendment, Securities, Protara Therapeutics, Fabbio, TARA, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.